Trial results

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

NCT07225829 on ClinicalTrials.gov · last registry update 2026-07-27

Closed to new participants; the 129 already enrolled are still being followed. Its estimated completion date, 28 August 2026, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for osteoarthritis — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

liraglutide

Victoza, Xultophy, Saxenda

Sponsor

4Moving Biotech

Sponsor type

Industry

Enrollment

129

Started

2025-06-17

Primary completion

2026-08-28 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline at Week 4 in the weekly average of Target Knee (TK) daily pain intensity using the WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain subscore

Conditions studied

Knee Osteoarthritis · Synovitis of Knee

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.